Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells.

Kim SM, Nguyen TT, Ravi A, Kubiniok P, Finicle BT, Jayashankar V, Malacrida L, Hou J, Robertson J, Gao D, Chernoff J, Digman MA, Potma EO, Tromberg BJ, Thibault P, Edinger AL.

Cancer Discov. 2018 Mar 23. pii: CD-17-1215. doi: 10.1158/2159-8290.CD-17-1215. [Epub ahead of print]

PMID:
29572236
2.

Pak2 regulates myeloid-derived suppressor cell development in mice.

Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E.

Blood Adv. 2017 Oct 10;1(22):1923-1933. doi: 10.1182/bloodadvances.2017007435. eCollection 2017 Oct 10.

3.

Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.

Araiza-Olivera D, Feng Y, Semenova G, Prudnikova TY, Rhodes J, Chernoff J.

Oncogene. 2018 Feb 15;37(7):944-952. doi: 10.1038/onc.2017.400. Epub 2017 Oct 23.

4.

Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression.

Zeng K, Tian L, Sirek A, Shao W, Liu L, Chiang YT, Chernoff J, Ng DS, Weng J, Jin T.

J Mol Cell Biol. 2017 Oct 1;9(5):384-394. doi: 10.1093/jmcb/mjx031.

PMID:
28992163
5.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27.

6.

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Tan Y, Sementino E, Chernoff J, Testa JR.

Am J Cancer Res. 2017 Aug 1;7(8):1724-1737. eCollection 2017.

7.

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J.

Cancer Res. 2017 Sep 15;77(18):5026-5038. doi: 10.1158/0008-5472.CAN-16-2834. Epub 2017 Jul 20.

PMID:
28729415
8.

Recent advances in methods to assess the activity of the kinome.

Radu M, Chernoff J.

F1000Res. 2017 Jun 26;6:1004. doi: 10.12688/f1000research.10962.1. eCollection 2017. Review.

9.

Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.

Semenova G, Stepanova DS, Dubyk C, Handorf E, Deyev SM, Lazar AJ, Chernoff J.

Oncogene. 2017 Sep 21;36(38):5421-5431. doi: 10.1038/onc.2017.143. Epub 2017 May 22.

10.

Targeting PAK1.

Semenova G, Chernoff J.

Biochem Soc Trans. 2017 Feb 8;45(1):79-88. doi: 10.1042/BST20160134. Review.

PMID:
28202661
11.

Alfred G. Knudson Jr, MD, PhD: In Memoriam (1922-2016).

Chernoff J.

Cancer Res. 2017 Feb 15;77(4):815-816. doi: 10.1158/0008-5472.CAN-16-3547. No abstract available.

12.

Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.

Semenova G, Stepanova DS, Deyev SM, Chernoff J.

Biochimie. 2017 Apr;135:1-5. doi: 10.1016/j.biochi.2017.01.001. Epub 2017 Jan 6.

13.

Group I Paks Promote Skeletal Myoblast Differentiation In Vivo and In Vitro.

Joseph GA, Lu M, Radu M, Lee JK, Burden SJ, Chernoff J, Krauss RS.

Mol Cell Biol. 2017 Feb 1;37(4). pii: e00222-16. doi: 10.1128/MCB.00222-16. Print 2017 Feb 15.

14.

Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.

Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, Arias-Romero LE.

Oncotarget. 2016 Nov 22;7(47):76590-76603. doi: 10.18632/oncotarget.12576.

15.

Tuning PAK Activity to Rescue Abnormal Myelin Permeability in HNPP.

Hu B, Arpag S, Zhang X, Möbius W, Werner H, Sosinsky G, Ellisman M, Zhang Y, Hamilton A, Chernoff J, Li J.

PLoS Genet. 2016 Sep 1;12(9):e1006290. doi: 10.1371/journal.pgen.1006290. eCollection 2016 Sep.

16.

Hras helps hippo heterodimerize to evade tumor suppression.

Araiza-Olivera D, Chernoff J.

Small GTPases. 2016 Aug 25:1-5. doi: 10.1080/21541248.2016.1228794. [Epub ahead of print]

PMID:
27560370
17.

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.

Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS.

Cell Rep. 2016 Aug 2;16(5):1273-1286. doi: 10.1016/j.celrep.2016.06.091. Epub 2016 Jul 21.

18.

The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.

Prudnikova TY, Chernoff J.

Small GTPases. 2017 Oct 2;8(4):193-198. doi: 10.1080/21541248.2016.1213089. Epub 2016 Jul 18.

19.

H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.

Rawat SJ, Araiza-Olivera D, Arias-Romero LE, Villamar-Cruz O, Prudnikova TY, Roder H, Chernoff J.

Curr Biol. 2016 Jun 20;26(12):1556-1563. doi: 10.1016/j.cub.2016.04.027. Epub 2016 May 26.

20.

p21-activated kinase 2 regulates HSPC cytoskeleton, migration, and homing via CDC42 activation and interaction with β-Pix.

Reddy PN, Radu M, Xu K, Wood J, Harris CE, Chernoff J, Williams DA.

Blood. 2016 Apr 21;127(16):1967-75. doi: 10.1182/blood-2016-01-693572. Epub 2016 Mar 1.

21.

Does salmon calcitonin cause cancer? A review and meta-analysis.

Wells G, Chernoff J, Gilligan JP, Krause DS.

Osteoporos Int. 2016 Jan;27(1):13-9. doi: 10.1007/s00198-015-3339-z. Epub 2015 Oct 5. Review.

22.

p21-Activated Kinase 2 Regulates Endothelial Development and Function through the Bmk1/Erk5 Pathway.

Radu M, Lyle K, Hoeflich KP, Villamar-Cruz O, Koeppen H, Chernoff J.

Mol Cell Biol. 2015 Dec;35(23):3990-4005. doi: 10.1128/MCB.00630-15. Epub 2015 Sep 21.

23.

Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.

Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J.

Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.

24.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

25.

Pak2 Links TCR Signaling Strength to the Development of Regulatory T Cells and Maintains Peripheral Tolerance.

O'Hagan KL, Choi J, Pryshchep O, Chernoff J, Phee H.

J Immunol. 2015 Aug 15;195(4):1564-77. doi: 10.4049/jimmunol.1500843. Epub 2015 Jul 8.

26.

Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice.

Singh NK, Kotla S, Dyukova E, Traylor JG Jr, Orr AW, Chernoff J, Marion TN, Rao GN.

Nat Commun. 2015 Jun 24;6:7450. doi: 10.1038/ncomms8450.

27.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, Huang W, McKew JC, Chernoff J, Forrest WF, Haverty PM, Chin SF, Rakha EA, Green AR, Ellis IO, Caldas C, O'Brien T, Friedman LS, Koeppen H, Rudolph J, Hoeflich KP.

Breast Cancer Res. 2015 Apr 23;17:59. doi: 10.1186/s13058-015-0564-5.

28.

Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.

Kosoff RE, Aslan JE, Kostyak JC, Dulaimi E, Chow HY, Prudnikova TY, Radu M, Kunapuli SP, McCarty OJ, Chernoff J.

Blood. 2015 May 7;125(19):2995-3005. doi: 10.1182/blood-2014-10-604504. Epub 2015 Mar 30.

29.

Regulation of mammalian Ste20 (Mst) kinases.

Rawat SJ, Chernoff J.

Trends Biochem Sci. 2015 Mar;40(3):149-56. doi: 10.1016/j.tibs.2015.01.001. Epub 2015 Feb 6. Review.

30.

Group I Paks as therapeutic targets in NF2-deficient meningioma.

Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J.

Oncotarget. 2015 Feb 10;6(4):1981-94.

31.

Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Zeng Y, Broxmeyer HE, Staser K, Chitteti BR, Park SJ, Hahn S, Cooper S, Sun Z, Jiang L, Yang X, Yuan J, Kosoff R, Sandusky G, Srour EF, Chernoff J, Clapp DW.

Stem Cells. 2015 May;33(5):1630-41. doi: 10.1002/stem.1951.

32.

Potential compensation among group I PAK members in hindlimb ischemia and wound healing.

Elsherif L, Ozler M, Zayed MA, Shen JH, Chernoff J, Faber JE, Parise LV.

PLoS One. 2014 Nov 7;9(11):e112239. doi: 10.1371/journal.pone.0112239. eCollection 2014.

33.

Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Prudnikova TY, Rawat SJ, Chernoff J.

Clin Cancer Res. 2015 Jan 1;21(1):24-9. doi: 10.1158/1078-0432.CCR-14-0827. Epub 2014 Oct 21. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1772.

34.

Gq-mediated Akt translocation to the membrane: a novel PIP3-independent mechanism in platelets.

Badolia R, Manne BK, Dangelmaier C, Chernoff J, Kunapuli SP.

Blood. 2015 Jan 1;125(1):175-84. doi: 10.1182/blood-2014-05-576306. Epub 2014 Oct 20.

35.

Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers.

Baker NM, Yee Chow H, Chernoff J, Der CJ.

Clin Cancer Res. 2014 Sep 15;20(18):4740-6. doi: 10.1158/1078-0432.CCR-13-1727. Review.

36.

Pak2 is required for actin cytoskeleton remodeling, TCR signaling, and normal thymocyte development and maturation.

Phee H, Au-Yeung BB, Pryshchep O, O'Hagan KL, Fairbairn SG, Radu M, Kosoff R, Mollenauer M, Cheng D, Chernoff J, Weiss A.

Elife. 2014 May 13;3:e02270. doi: 10.7554/eLife.02270.

37.

A Pak1/Erk signaling module acts through Gata6 to regulate cardiovascular development in zebrafish.

Kelly ML, Astsaturov A, Rhodes J, Chernoff J.

Dev Cell. 2014 May 12;29(3):350-9. doi: 10.1016/j.devcel.2014.04.003.

38.

Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice.

Chiang YT, Ip W, Shao W, Song ZE, Chernoff J, Jin T.

Endocrinology. 2014 Jun;155(6):2122-32. doi: 10.1210/en.2013-1743. Epub 2014 Mar 31.

PMID:
24684301
39.

PAK signalling during the development and progression of cancer.

Radu M, Semenova G, Kosoff R, Chernoff J.

Nat Rev Cancer. 2014 Jan;14(1):13-25. Review.

40.

Analysis of PTP1B sumoylation.

Saha S, Chernoff J.

Methods. 2014 Jan 15;65(2):201-6. doi: 10.1016/j.ymeth.2013.09.012. Epub 2013 Sep 25.

41.

p21-Activated kinase (PAK) regulates cytoskeletal reorganization and directional migration in human neutrophils.

Itakura A, Aslan JE, Kusanto BT, Phillips KG, Porter JE, Newton PK, Nan X, Insall RH, Chernoff J, McCarty OJ.

PLoS One. 2013 Sep 3;8(9):e73063. doi: 10.1371/journal.pone.0073063. eCollection 2013.

42.

FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL.

J Biol Chem. 2013 Oct 4;288(40):29105-14. doi: 10.1074/jbc.M113.510933. Epub 2013 Aug 19.

43.

Targeting Cdc42 in cancer.

Arias-Romero LE, Chernoff J.

Expert Opin Ther Targets. 2013 Nov;17(11):1263-73. doi: 10.1517/14728222.2013.828037. Epub 2013 Aug 19. Review.

44.

The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation.

Aslan JE, Baker SM, Loren CP, Haley KM, Itakura A, Pang J, Greenberg DL, David LL, Manser E, Chernoff J, McCarty OJ.

Am J Physiol Cell Physiol. 2013 Sep;305(5):C519-28. doi: 10.1152/ajpcell.00418.2012. Epub 2013 Jun 19.

45.

ArhGAP15, a Rac-specific GTPase-activating protein, plays a dual role in inhibiting small GTPase signaling.

Radu M, Rawat SJ, Beeser A, Iliuk A, Tao WA, Chernoff J.

J Biol Chem. 2013 Jul 19;288(29):21117-25. doi: 10.1074/jbc.M113.459719. Epub 2013 Jun 11.

46.

Role of p21-activated kinases in cardiovascular development and function.

Kelly ML, Astsaturov A, Chernoff J.

Cell Mol Life Sci. 2013 Nov;70(22):4223-8. doi: 10.1007/s00018-013-1347-8. Epub 2013 May 4. Review.

47.

p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear.

Aslan JE, Itakura A, Haley KM, Tormoen GW, Loren CP, Baker SM, Pang J, Chernoff J, McCarty OJ.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1544-51. doi: 10.1161/ATVBAHA.112.301165. Epub 2013 May 2.

48.

Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.

Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Chernoff J.

Cancer Res. 2013 Jun 15;73(12):3671-82. doi: 10.1158/0008-5472.CAN-12-4453. Epub 2013 Apr 10.

49.

An in vivo assay to test blood vessel permeability.

Radu M, Chernoff J.

J Vis Exp. 2013 Mar 16;(73):e50062. doi: 10.3791/50062.

50.

The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 protein.

Rawat SJ, Creasy CL, Peterson JR, Chernoff J.

J Biol Chem. 2013 Mar 22;288(12):8762-71. doi: 10.1074/jbc.M112.414524. Epub 2013 Feb 5.

Supplemental Content

Loading ...
Support Center